Niki BioSolutions Initiates $1.4M At-the-Market Stock Offering with H.C. Wainwright & Co.
On October 9, 2026, Niki BioSolutions, Inc. entered into an At the Market Offering Agreement with H.C. Wainwright & Co., ...
Model output · Signal date 2026-10-14
Niki Biosolutions, Inc. (NIKI) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
▼ Bearish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Bottom 35%
of 4009 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$2M
small-cap · #9 of 9 peers
Summary
Niki Biosolutions, Inc. (NIKI) stock forecast summary
Our AI ranks Niki Biosolutions, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Niki Biosolutions, Inc. is a small-cap company with a market capitalization of $2M. It ranks number 9 by market capitalization among the 9 Measuring & Controlling Devices, NEC issuers in our coverage with a current forecast. Its P/B Ratio of 0.08x is the lowest of the 9 peers that report one.
A per-ticker accuracy statistic for NIKI is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NIKI included.
Follow NIKI freePrice
NIKI price chart and AI forecast
Cross-section · 2026-10-14
How NIKI ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Niki Biosolutions, Inc. (NIKI) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Measuring & Controlling Devices, NEC peers listed below that report each metric.
Valuation & Market
| Metric | NIKI | Rank |
|---|---|---|
| Market Cap | $2M | 9/9 |
| P/B Ratio | 0.08x | 9/9 |
| Book Value/Share | $31.44 | – |
Financial Health
| Metric | NIKI | Rank |
|---|---|---|
| D/E Ratio | 0.21x | 9/11 |
| Financial Leverage | 0.81x | 11/11 |
Dividend & Shareholder Information
| Metric | NIKI | Rank |
|---|---|---|
| Shares Outstanding | 1M | – |
Balance Sheet Highlights (USD millions)
| Accounts Receivable | $110K | 0.4% of assets |
| Total Liabilities | $5M | 16.9% of assets |
Quarterly Financial Reports
NIKI quarterly financials and insider trading
Industry Peers · Measuring & Controlling Devices, NEC
Niki Biosolutions, Inc. (NIKI) industry peers
Companies classified under the same SEC industry code as Niki Biosolutions, Inc. (Measuring & Controlling Devices, NEC): 11 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| NIKI Niki Biosolutions, Inc. | ▼ | $2M |
| TMO Thermo Fisher Scientific Inc. | ▼ | $245.16B |
| ROK Rockwell Automation, Inc | ▼ | $48.01B |
| TRMB Trimble Inc. | ▶ | $13.99B |
| ONTO Onto Innovation Inc. | ▲ | $12.93B |
| MIR Mirion Technologies, Inc. | ▲ | $4.09B |
| OWLT Owlet, Inc. | ▲ | $135M |
| GEOS Geospace Technologies Corp | ▲ | $61M |
| BCHT Birchtech Corp. | ▶ | $37M |
| AATC Autoscope Technologies Corp | ▼ | N/A |
| QSI Quantum-Si Inc | ▲ | N/A |
Where NIKI sits on the market map
Industrial Applications and Services · Measuring & Controlling Devices, NEC
News
Niki Biosolutions, Inc. (NIKI) stock news
Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Alidad Mireskandari, Ph.D., President and COO of Niki BioSolutions, will hold a live presentation on September 14 at 10:30 AM EST and will also be available for in-person or virtual 1x1 meetings ...
Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
NEW HAVEN, CT and PRINCETON, NJ, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality ...
FAQ
Niki Biosolutions, Inc. (NIKI) stock forecast FAQ
What is the Niki Biosolutions, Inc. (NIKI) stock forecast?
Our AI ranks Niki Biosolutions, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Niki Biosolutions, Inc. stock predictions?
A per-ticker accuracy statistic for NIKI is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Niki Biosolutions, Inc. forecasts updated?
Niki Biosolutions, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Niki Biosolutions, Inc.'s industry peers?
11 issuers in our coverage, NIKI included, share the SEC industry code Measuring & Controlling Devices, NEC. The largest are: Thermo Fisher Scientific Inc. (TMO), Rockwell Automation, Inc (ROK), Trimble Inc. (TRMB), Onto Innovation Inc. (ONTO), Mirion Technologies, Inc. (MIR), Owlet, Inc. (OWLT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.